H002
Phase 2Small molecule
H002 is one of 16 small molecule programs targeting EGFR Mutation. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Locally Advanced or Metastatic NSCLC
#DrugCompanyPhaseTrials
1Tagrisso
AstraZenecaPhase 3
Tecentriq
RochePhase 2
Lumakras
AmgenPhase 2
Vebreltinib
AAvistone Biotechnology Co., Ltd.
Phase 3
PLB1004
AAvistone Biotechnology Co., Ltd.
Phase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 3
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
Disitamab Vedotin
PfizerPhase 2
Pyrotinib
HHengrui Therapeutics, Inc.
Phase 2
ASK120067
JJiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for H002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRedCloud Bio